1. Scrip

Israel's BiondVax To Take 'More Global View' With NASDAQ-Only Listing

 
• By Sten Stovall

BiondVax's CEO tells Scrip why the Israel-based vaccine maker wants to delist there and only have a US-based NASDAQ listing and re-make its executive board in to one that's more internationally experienced.

Nasdaq
BiondVax Says Being Soley NASDAQ-Listed Will Help Make It More Internationally-Minded • Source: Shutterstock

BiondVax Pharmaceuticals Ltd. wants to "spread its wings" now that it is adequately funded to progress its lead flu vaccine candidate – but to do that BiondVax feels it must delist from the Tel Aviv Stock Exchange while maintaining a continued listing on NASDAQ, and rebuild its executive board into one that is more commercially minded.

"We are now ready to concentrate our attention on just one exchange as we move forward," Ron Babecoff, BiondVax's CEO...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business